ARCOMA Arcoma AB

Arcoma launches new X-ray system OMNERA 500A on the US market

Arcoma launches new X-ray system OMNERA 500A on the US market

2020-12-01

PRESSRELEASE 

Arcoma launches new X-ray system OMNERA 500A on the US market



Arcoma AB today launches the new X-ray system Omnera 500A on the American market. OMNERA 500A Includes New Intelligent Automation Features to Help Improve Workflow and Efficiency, Without Compromising on Patient Care.

The OMNERA 500A offers outstanding performance and intelligent automation with features that puts efficiency and patient safety first. The system has a new design and a new modern user interface with smart functions that simplify workflow and are designed to facilitate disinfection. The OMNERA 500A also has a completely new wall stand and an updated X-ray table that improves the patient and user experience.

The OMNERA 500A is launched through Arcoma's partner Canon Medical Systems USA at the annual meeting RSNA, which this year will be held virtual. The fair runs this week. To see the new system in Canon Medical Systems' virtual booth, visit their website:

“Today’s hospitals are challenged with productivity and workflow demands like never before, and it’s imperative that their x-ray systems are able to perform seamlessly so that they can focus on their patients,” said Jay Aboujaoude, managing director, X-Ray Business Unit, Canon Medical Systems USA, Inc. “The OMNERA 500A meets that need so that technologists can produce images with exceptional image quality, made possible with the unparalleled Canon CXDI detector technology that is at the heart of the system.”

“It feels very good to launch the OMNERA 500A that is desired by our partner and the market. We are convinced that the launch of the product will help us increase sales and customer satisfaction in the future. Canon Medical Systems USA has prepared a fantastic professional virtual booth with a big focus on the new product, which will be exciting to see during the week." says Linda Ungsten, product manager at Arcoma.

About Canon Medical Systems USA

Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website at .

About Canon Medical Systems Corporation

Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. For more information, visit the Canon Medical website: .

OMNERA is a registered trademark of CANON MEDICAL SYSTEMS USA, INC. Made for Life is a trademark of Canon Medical Systems Corporation. CXDI is registered trademarks of Canon in the United States and may also be registered trademarks or trademarks in other countries.

About Arcoma

Arcoma, with long experience in the industry, is a leading provider of integrated digital X-ray systems with high quality and advanced technology. Arcoma’s products offer the latest digital imaging technology combined with technically advanced moving positioning systems and ergonomic Scandinavian design. Arcoma offers the customers complete, configurable and functional digital x-ray systems. The company's products are sold through retailers as well as OEM customers and today there are over 3,500 of Arcoma’s X-ray systems installed worldwide. Arcoma is listed on Nasdaq First North. For more information about Arcoma, please visit

For more information, please contact:

Sanna Rydberg, Phone: +46 706 069548, E-mail:  

The information was submitted, through the CEO, for publication on December 1, 2020 at. 8.30 AM.

For more IR-related information and the possibility of pressrelease prenumeration, please visit our IR page:



EN
01/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcoma AB

 PRESS RELEASE

Arcoma avslutar avtal om likviditetsgaranti

Arcoma avslutar avtal om likviditetsgaranti PRESSRELEASE 2025-06-30 Arcoma avslutar avtal om likviditetsgaranti Arcoma har avslutat avtalet med DNB Carnegie Investment Bank AB, där DNB Carnegie har verkat som likviditetsgarant för bolaget. Syftet med garantin har varit att främja likviditeten i bolagets aktie, minska volatiliteten samt underlätta handel. Arcoma bedömer att rådande handel och därmed likviditeten i aktien är god och att behovet av en likviditetsgarant är begränsad. DNB Carnegies uppdrag avslutas tisdag den första juli 2025. Om Arcoma Arcoma, med lång erfarenhet av brans...

 PRESS RELEASE

Arcoma AB successfully completes directed share issue of SEK 11.0 mill...

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR) Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. PLEASE REFER...

 PRESS RELEASE

Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSE...

Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSEK (~1 MEUR) (MAR) Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSEK (~1 MEUR) EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. SE AVSNITTET "VIKTIG INFOR...

 PRESS RELEASE

Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025

Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025 PRESSRELEASE 2025-05-14 Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025 Idag, den 14 maj 2025, hölls årsstämma i Arcoma Aktiebolag. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdispositionÅrsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat ienlighet med styrelsens förslag i årsr...

 PRESS RELEASE

Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA d...

Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA dämpar kvartalet något. (MAR) PRESSRELEASE 2025-04-29 Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA dämpar kvartalet något. (MAR) FINANSIELLT SAMMANDRAG Första kvartalet Nettoomsättningen för kvartalet uppgick till 34 875 (46 464) kSEK EBITDA (rörelseresultat före avskrivningar) uppgick till 4 458 (6 493) kSEK EBITDA-marginalen uppgick till 12% (14%)Resultat före skatt uppgick till 2 582 (4 502) kSEKResultat per aktie 0,16 (0,27) SEK VIKTIGA HÄNDELSER I PERIODEN• Inga händelser att rapportera. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch